View all the latest information in graft-versus-host disease, arranged by trials and clinical studies. Listed below are recently added trial updates.
Targeting CD6+ T cells as a promising strategy for treating acute GvHD: An interview with Benedetta Rambaldi
Benedetta Rambaldi, MD, is a hematologist, a PhD student at the University of...
Positive interim results of the EQUATE study—Itolizumab for acute graft-versus-host disease
Positive interim data from the initial two cohorts of the phase Ib, open-label, dose-escalation portion of...
Editorial theme | Latest updates on cGvHD treatment
First-line treatment for chronic graft-versus-host disease (cGvHD), which consists of steroids, has not changed much over the last three decades. In...
FDA accepts a supplemental new drug application for ruxolitinib in steroid-refractory cGvHD
On February 22, 2021, the U.S. Food and Drug Administration (FDA) granted priority review to a supplemental...
Updated results from REACH2: Ruxolitinib for steroid-refractory acute GvHD
As previously reported on the GvHD Hub, the initial data from the phase III REACH2 trial uncovered the potential benefit of...
REACH2 study: What is the risk of losing response to ruxolitinib over time?
During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub...
Phase II HERACLES trial meets its primary objective
On March 17, 2021, it was announced that the phase II HERACLES trial (NCT03359980), evaluating MaaT013 in patients with acute graft-versus-host...
The results of the expanded access program using MaaT013 for steroid-refractory GI GvHD
Gastrointestinal acute graft-versus-host disease (GI aGvHD) is a serious complication of stem cell...
BMT CTN 1101
BMT CTN 1202
BMT CTN 1203
BMT CTN 1501